BACKGROUND: A study was undertaken to analyze the survival of chronic lymphocytic leukemia (CLL) patients relative to age-matched individuals in the general population and determine the age-stratified utility of prognostic testing. METHODS: All 2487 patients diagnosed with CLL between January 1995 and June 2008 and cared for in the Mayo Clinic Division of Hematology were categorized by age at diagnosis and evaluated for differences in clinical characteristics, time to first treatment, and overall survival (OS). RESULTS: Among Rai stage 0 patients, survival was shorter than the age-matched general population for patients aged <55 years (P < .001), 55 to 64 years (P < .001), and 65 to 74 years (P < .001), but not those aged ≥75 years at diagnosis (P = not significant). CD38, IGHV mutation, and ZAP-70 each predicted time to first treatment independent of stage for all age groups (all P < .04), but had less value for predicting OS, particularly as age increased. IGHV and fluorescent in situ hybridization (FISH) predicted OS independent of stage for patients aged <55 years (P ≤ .001), 55 to 64 years (P ≤ .004), and 65 to 74 years (P ≤ .001), but not those aged ≥75 years. CD38 and ZAP-70 each predicted OS independent of stage for only 2 of 4 age categories. Among Rai 0 patients aged <75 years, survival was shorter than the age-matched population only for IGHV unmutated (P < .001) patients or those with unfavorable FISH (P < .001). CONCLUSIONS: Survival of CLL patients aged <75 years is shorter than the age-matched general population regardless of disease stage. Among patients aged <75 years, the simple combinations of stage and IGHV or stage and FISH identifies those with excess risk of death relative to the age-matched population. Although useful for predicting time to first treatment independent of stage for patients of all ages, prognostic testing had little utility for predicting OS independent of stage among patients aged ≥75 years.
BACKGROUND: A study was undertaken to analyze the survival of chronic lymphocytic leukemia (CLL) patients relative to age-matched individuals in the general population and determine the age-stratified utility of prognostic testing. METHODS: All 2487 patients diagnosed with CLL between January 1995 and June 2008 and cared for in the Mayo Clinic Division of Hematology were categorized by age at diagnosis and evaluated for differences in clinical characteristics, time to first treatment, and overall survival (OS). RESULTS: Among Rai stage 0 patients, survival was shorter than the age-matched general population for patients aged <55 years (P < .001), 55 to 64 years (P < .001), and 65 to 74 years (P < .001), but not those aged ≥75 years at diagnosis (P = not significant). CD38, IGHV mutation, and ZAP-70 each predicted time to first treatment independent of stage for all age groups (all P < .04), but had less value for predicting OS, particularly as age increased. IGHV and fluorescent in situ hybridization (FISH) predicted OS independent of stage for patients aged <55 years (P ≤ .001), 55 to 64 years (P ≤ .004), and 65 to 74 years (P ≤ .001), but not those aged ≥75 years. CD38 and ZAP-70 each predicted OS independent of stage for only 2 of 4 age categories. Among Rai 0 patients aged <75 years, survival was shorter than the age-matched population only for IGHV unmutated (P < .001) patients or those with unfavorable FISH (P < .001). CONCLUSIONS: Survival of CLLpatients aged <75 years is shorter than the age-matched general population regardless of disease stage. Among patients aged <75 years, the simple combinations of stage and IGHV or stage and FISH identifies those with excess risk of death relative to the age-matched population. Although useful for predicting time to first treatment independent of stage for patients of all ages, prognostic testing had little utility for predicting OS independent of stage among patients aged ≥75 years.
Authors: Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier Journal: Blood Date: 2002-02-01 Impact factor: 22.113
Authors: D F Jelinek; R C Tschumper; S M Geyer; N D Bone; G W Dewald; C A Hanson; M J Stenson; T E Witzig; A Tefferi; N E Kay Journal: Br J Haematol Date: 2001-12 Impact factor: 6.998
Authors: Gerard Tobin; Ulf Thunberg; Anna Johnson; Ingrid Thörn; Ola Söderberg; Magnus Hultdin; Johan Botling; Gunilla Enblad; Jan Sällström; Christer Sundström; Göran Roos; Richard Rosenquist Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: Alexander Kröber; Till Seiler; Axel Benner; Lars Bullinger; Elsbeth Brückle; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer Journal: Blood Date: 2002-08-15 Impact factor: 22.113
Authors: N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield Journal: J Clin Oncol Date: 1999-12 Impact factor: 44.544
Authors: H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter Journal: N Engl J Med Date: 2000-12-28 Impact factor: 91.245
Authors: Gordon W Dewald; Stephanie R Brockman; Sarah F Paternoster; Nancy D Bone; Judith R O'Fallon; Cristine Allmer; Charles D James; Diane F Jelinek; Renee C Tschumper; Curtis A Hanson; Rajiv K Pruthi; Thomas E Witzig; Timothy G Call; Neil E Kay Journal: Br J Haematol Date: 2003-04 Impact factor: 6.998
Authors: Sigurdur Y Kristinsson; Paul W Dickman; Wyndham H Wilson; Neil Caporaso; Magnus Björkholm; Ola Landgren Journal: Haematologica Date: 2009-09 Impact factor: 9.941
Authors: Tait D Shanafelt; Neil E Kay; Kari G Rabe; David J Inwards; Clive S Zent; Jose F Leis; Susan M Schwager; Carrie A Thompson; Deborah A Bowen; Thomas E Witzig; Susan L Slager; Timothy G Call Journal: Cancer Date: 2011-08-26 Impact factor: 6.860
Authors: Alessandra Ferrajoli; Tait D Shanafelt; Cristina Ivan; Masayoshi Shimizu; Kari G Rabe; Nazila Nouraee; Mariko Ikuo; Asish K Ghosh; Susan Lerner; Laura Z Rassenti; Lianchun Xiao; Jianhua Hu; James M Reuben; Steliana Calin; M James You; John T Manning; William G Wierda; Zeev Estrov; Susan O'Brien; Thomas J Kipps; Michael J Keating; Neil E Kay; George A Calin Journal: Blood Date: 2013-07-02 Impact factor: 22.113
Authors: Sameer A Parikh; Jose F Leis; Kari G Chaffee; Timothy G Call; Curtis A Hanson; Wei Ding; Asher A Chanan-Khan; Deborah Bowen; Michael Conte; Susan Schwager; Susan L Slager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt Journal: Cancer Date: 2015-04-30 Impact factor: 6.860
Authors: Juhi Ojha; Jackline Ayres; Charla Secreto; Renee Tschumper; Kari Rabe; Daniel Van Dyke; Susan Slager; Tait Shanafelt; Rafael Fonseca; Neil E Kay; Esteban Braggio Journal: Blood Date: 2014-11-06 Impact factor: 22.113
Authors: Stefano Molica; Tait D Shanafelt; Diana Giannarelli; Massimo Gentile; Rosanna Mirabelli; Giovanna Cutrona; Luciano Levato; Nicola Di Renzo; Francesco Di Raimondo; Caterina Musolino; Francesco Angrilli; Angelo Famà; Anna Grazia Recchia; Kari G Chaffee; Antonino Neri; Neil E Kay; Manlio Ferrarini; Fortunato Morabito Journal: Am J Hematol Date: 2016-08-08 Impact factor: 10.047